ProCE Banner Activity

Phase I Study: MCARH171 BCMA-Targeted CAR T-Cells in Advanced Multiple Myeloma

Slideset Download
Conference Coverage
A new human scFv-derived BCMA-targeted CAR T-cell appears tolerable with no reported dose-limiting toxicity and preliminary evidence of activity in patients with heavily pretreated myeloma.

Released: December 15, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology